Andreas Tridimas
@lipidologist.bsky.social
NHS Chemical Pathologist with a principal interest in Lipids. Wirral & Chester. Views my own.
Reposted by Andreas Tridimas
Muvalaplin, a small-molecule lipoprotein(a) inhibitor, produced substantial reductions in lipoprotein(a) levels in patients at high risk of cardiovascular events.
ja.ma/42lnypM
#MedSky #CardioSky
ja.ma/42lnypM
#MedSky #CardioSky
January 21, 2025 at 7:55 PM
Muvalaplin, a small-molecule lipoprotein(a) inhibitor, produced substantial reductions in lipoprotein(a) levels in patients at high risk of cardiovascular events.
ja.ma/42lnypM
#MedSky #CardioSky
ja.ma/42lnypM
#MedSky #CardioSky
Reposted by Andreas Tridimas
Muvalaplin, a small-molecule lipoprotein(a) inhibitor, produced substantial reductions in lipoprotein(a) levels in patients at high risk of cardiovascular events. #AHA24
https://ja.ma/49cQrpT
https://ja.ma/49cQrpT
November 18, 2024 at 8:15 PM
Muvalaplin, a small-molecule lipoprotein(a) inhibitor, produced substantial reductions in lipoprotein(a) levels in patients at high risk of cardiovascular events. #AHA24
https://ja.ma/49cQrpT
https://ja.ma/49cQrpT
Reposted by Andreas Tridimas
Most viewed in the last 7 days from JAMA:
Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated.
https://ja.ma/4g7qutR
Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated.
https://ja.ma/4g7qutR
November 28, 2024 at 5:00 PM
Most viewed in the last 7 days from JAMA:
Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated.
https://ja.ma/4g7qutR
Muvalaplin reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated.
https://ja.ma/4g7qutR